Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • TA258
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology will be considered for review in April 2013. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
June 2012